Regional and cellular distribution patterns of insulin-degrading enzyme in the adult human brain and pituitary

Journal of Chemical Neuroanatomy

Volumn 35, Issue 2, 2008, Pages 216-224

  Bernstein, Hans Gert ^a   Lendeckel, Uwe ^a   Bukowska, Alicja ^a   Ansorge, Siegfried ^b   Ernst, Theresia ^a   Stauch, Renate ^a   Trübner, Kurt ^c   Steiner, Johann ^a   Dobrowolny, Henrik ^a   Bogerts, Bernhard ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Institute of Medical Technology GmbH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Blood vessels; Human brain; Immunohistochemistry; Insulin degrading enzyme; Neurons; Oligodendrocytes; Pituitary

Indexed keywords

INSULINASE;

ADULT; ANTIBODY LABELING; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELLULAR DISTRIBUTION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROHYPOPHYSIS; OLIGODENDROGLIA; PRIORITY JOURNAL; WESTERN BLOTTING;

ADULT; BRAIN; CADAVER; CAUSE OF DEATH; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULYSIN; MALE; MIDDLE AGED; PITUITARY GLAND; POSTMORTEM CHANGES;

EID: 39149099122     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2007.12.001     Document Type: Article

References (49)

1. Ansorge S., Bohley P., Kirschke H., Langner J., and Wiederanders B. The insulin and glucagon degrading proteinase of rat liver. Separation of the proteinasefrom the thiol proteindisulfide oxidoreductase. Biomed. Biochim. Acta 43 (1984) 29-38
2. Ansorge S., Bohley P., Kirschke H., Langner J., and Wiederanders B. The insulin-and glucagon degrading proteinase of rat liver: a metal dependent enzyme. Biomed. Biochim. Acta 43 (1984) 39-46
3. Atwood C.S., Melthal S.V., Lin T., Wilson A.C., Gallego M., Smith M.A., and Bonen R.L. Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence. J. Neuropathol. Exp. Neurol. 64 (2005) 93-103
4. Authier F., Posner B.I., and Bergeron J.J. Insulin-degrading enzyme. Clin. Invest. Med. 19 (1996) 149-160
5. Azam M., Gupta B.L., Gupta G., Jain S., and Baquer N.Z. Rat brain insulin-degrading enzyme in insulin and thyroid imbalances. Biochem. Int. 21 (1990) 321-329
6. Baumeister H., Müller D., Rehbein M., and Richter D. The rat insulin-degrading enzyme of mammals and bacteria. Methods Enzymol. 248 (1995) 693-703
7. Bennett R.G., Hamel F.G., and Duckworth W.C. Identification and isolation of a cytosolic proteolytic complex containing insulin degrading enzyme and the multicatalytic proteinase. Biochem. Biophys. Res. Commun. 202 (1994) 1047-1053
8. Bernstein H.-G. Proteases and Alzheimer's disease: present knowledge and emerging concepts of therapy. In: Lendeckel U., and Hooper N.G. (Eds). Proteases in the Brain (2005), Springer, New York 1-23
9. Bernstein H.-G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., Falkai P., and Bogerts B. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83 (1998) 867-875
10. Bernstein H.-G., Ansorge S., Riederer P., Frölich L., and Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci. Lett. 263 (1999) 161-164
11. Bernstein H.-G., Baumann B., Danos P., Diekmann S., Bogerts B., Gundelfinger E.D., and Braunewell K.H. Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and vilip-3) in human brain. J. Neurocytol. 28 (1999) 655-662
12. Bernstein H.-G., Krell D., Braunewell K.-H., Baumann B., Gundelfinger E.D., Diekmann S., Danos P., and Bogerts B. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dendate nucleus neurons in schizophrenia. J. Neurocytol. 30 (2001) 661-670
13. Bernstein H.-G., Sahin J., Smalla K.-H., Gundelfinger E.D., Bogerts B., and Kreutz M.R. A reduced number of cortical neurons show increased caldendrin protein levels in chronic schizophrenia. Schizophr. Res. 96 (2007) 246-256
14. Chadwick W., Wilson G., van de Venter M., Oelofsen W., and Roux S. Shifts in metabolic parameters surrounding glucose homeostasis resulting from tricyclic antidepressant therapy: implications of insulin resistance?. J. Pharm. Pharmacol. 59 (2007) 95-103
15. Cole A.R., Astell A., Green C., and Sutherland C. Molecular connexions between dementia and diabetes. Neurosci. Biobehav. Rev. 31 (2007) 1046-1063
16. Collin R.W., and Martens G.J. The amyloid-beta precursor-like protein APLP-2 and its relative APP are differentially regulated during neuroendocrine cell activation. Mol. Cell. Neurosci. 30 (2005) 429-436
17. Cook D.G., Leverenz J.B., McMillian P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., and Craft S. Reduced hippocampal insulin-degrading enzyme in later-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 162 (2003) 313-319
18. Crossgrove J.S., Smith E.L., and Zheng W. Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. Brain Res. 23 (2007) 187-195
19. De la Monte S., and Wands J.R. Review of insulin and insulin-like expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimer's Dis. 7 (2005) 45-61
20. Del Carmen Camberos M., and Cresto J.C. Insulin-degrading enzyme hydrolyzes ATP. Exp. Biol. Med. 232 (2007) 281-292
21. Dorn A., Bernstein H.-G., Rinne A., Ziegler M., Hahn H.-J., and Ansorge S. Insulin-and glucagonlike peptides in the brain. Anat. Rec. 207 (1983) 69-77
22. Frölich L., Blum-Degen D., Bernstein H.-G., Engelsberger S., Humrich J., Laufer S., Muschner D., Thalheimer A., Türk A., Hoyer S., Zöchling R., Boissl K.W., Jellinger K., and Riederer P. Brain insulin and insulin receptors in aging and sproadic Alzheimer's disease. J. Neural Transm. 105 (1998) 423-438
23. Gao W., Eisenhauer P.B., Conn K., Lynch J.A., Wells J.M., Ullman M.D., McKee A., Tahtte H.S., and Fine R.E. Insulin degrading enzyme is expressed in the human cerebrovascular endothelium and in cultured human cerebrovascular cells. Neurosci. Lett. 37 (2004) 6-11
24. Gupta R.C., Mishra S., Mishima T., Goldstein S., and Sabbah H.H. Reduced sarcoplasmic reticulum (Ca2+)-uptake and expression of phospholamaban in left ventricular myocardium of dogs with heart failure. J. Mol. Cell. Cardiol. 31 (1999) 1381-1389
25. Henneberg N., and Hoyer S. Desensitization of neuronal insulin receptor: a new approach in the aetiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)?. Arch. Gerontol. Geriatr. 21 (1995) 63-74
26. Hersh L.B. The insulysin (insulin degrading enzyme) enigma. Cell. Mol. Life Sci. 63 (2006) 2432-2434
27. Keilhoff G., Seidel B., Reiser M., Stanarius A., Huang P.L., Bogerts B., Wolf G., and Bernstein H.-G. Lack of neuronal NOS has consequences for the expression of POMC and POMC-derived peptides in the mouse pituitary. Acta Histochem. 103 (2001) 397-412
28. Kim M., Hersh L.B., Leissring M.A., Ingelsson M., Matsui T., Farris W., Lu A., Hyman B.T., Selkoe D.J., Bertram L., and Tanzi R.E. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem. 282 (2007) 7825-7832
29. Kurochkin V., and Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345 (1994) 33-37
30. Leal M.C., Dorfman V.B., Gamba A.F., Frangione B., Wisniewski T., Castaño E.M., Sigurdsson E.M., and Morelli L. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. Neuropathol. Exp. Neurol. 65 (2006) 976-987
31. McDermott J.R., and Gibson A.M. Degradation of Alzheimer's beta-amyloid protein by human and rat peptidases: involvement of insulin-degrading enzyme. Neurochem. Res. 22 (1997) 49-56
32. McNamara M.J., Ruff C.T., Wasco W., Tanzi R.E., Thiakaran G., and Hyman B.T. Immunohistochemical and in situ analysis of amyloid precursor-like protein-1 and amyloid precursor-like protein-2 expression in Alzheimer disease and aged control brains. Brain Res. 804 (1998) 45-51
33. Morelli L., Llovera R.E., Mathov I., Lue L.-F., Frangione B., Ghiso J., and Castano M. Insulin-degrading enzyme in brain microvessels. Proteolysis odf amyloid variants and reduced activity in cerebral amyloid angiopathy. J. Biol. Chem. 279 (2004) 56004-56013
34. Müller D., Baumeister H., Buck F., and Richter D. Atrial natriuretic peptide (ANP) is a highly affinity substrate for rat brain insulin-degrading enzyme. Eur. J. Biochem. 202 (1991) 285-292
35. Ogawa W., Shii K., Yonezawa S., Baba S., and Yokono K. Affinity purification of insulin-degrading enzyme and its endogenous inhibitor from rat liver. J. Biol. Chem. 267 (1992) 1310-1316
36. Omori Y., and Zahnd G. Insulin degradation by the rat adenopituitary. J. Jap. Diabetes Soc. 23 (1980) 1-9
37. Qiu W.Q., and Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2006) 190-198
38. Reiser M., Bernstein H.-G., Ansorge S., and Dorn A. Proteolytic degradation of insulin and glucagon in rat brain during ontogenesis. Acta Histochem. 82 (1987) 35-39
39. Roth R.A., Mesirow M.L., Yokono K., and Baba S. Degradation of insulin-like growth factors I and II by a human insulin-degrading enzyme. Endocr. Res. 10 (1984) 101-112
40. Runyan G., Duckworth W.C., Kitabchi A.E., and Huff G. The effect of age on insulin degrading enzyme activity in rat tissue. Diabetes 28 (1979) 324-325
41. Safavi A., Miller B.C., Cottam L., and Hersh L.B. Identification of gamma-endorphin-generating enzyme as insulin-degrading enzyme. Biochemistry 35 (1996) 14318-14325
42. Saric T., Müller D., Seitz H.J., and Pavelic K. Non-covalent interaction of ubiquitin with insulin-degrading enzyme. Mol. Cell. Endocrinol. 204 (2003) 11-20
43. Schulingkamp R.J., Pagano T.C., Hung D., and Raffa R.B. Insulin receptors and insulin action in the brain: a review and clinical applications 24 (2000) 855-872
44. Selemon L.D., Mrzljak J., Kleinman J.E., Herman M.M., and Goldman-Rakic P.S. Regional specificity in the neuronal substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. Arch. Gen. Psychiatry 60 (2003) 69-77
45. Spiechowicz M., Bernstein H.-G., Dobrowolny H., Lesniak W., Mawrin C., Bogerts B., Kuznicki J., and Filipek A. Density of Sgt-1 immunopositive neurons is decreased in the cerebral cortex of Alzheimer's disease brain. Neurochem. Int. 49 (2006) 487-493
46. Sweep C.G., Boersma C.J., and Wiegant V.M. Effects of chronic treatment with haloperidol and bromocriptine on the processing of beta-endorphin to gamma-and alpha-endorphin in discrete ragions of the rat pituitary gland and brain. Neuropharmacology 29 (1990) 61-68
47. Unger J.W., and Lange W. Insulin receptors in the pituitary gland: morphological evidence for influence on opioid peptide-synthesizing cells. Cell Tissue Res. 288 (1997) 471-483
48. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., and Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20 (2000) 1657-1665
49. Zhao R., Ksiezak-Reding H., Riggio S., Haroutunian V., and Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr. Res. 84 (2006) 1-14